MSTN and muscular dystrophy: In addition, decreased GDF8 levels (both within muscle and systemically) have been reported in patients with muscular dystrophy and older adults who show greater disease progression/muscle wasting (63, 64), which would limit the effectiveness of anti-GDF8 strategies.